OXIGENE GETS POSITIVE RESULTS OP PHASE II STUDY OF CA4P

摘要

OXiGENE,Inc.(NASDAQ:OXGN,XSSE:OXGN),Waltham,Mass.,has completed a Phase II Study in patients with advanced imageable malignancies.This was a randomized open-label study of intravenous CA4P administered at 45 or 63 mg/m2 followed by paclitaxel and carboplatin in 13 patients.The objectives of the trial were to identify optimal dose of CA4P for blood flow shutdown and to demonstrate safety and efficacy of CA4P in combination with paclitaxel and carboplatin.All patient data have been collected and analyzed,with the exception of one patient who is still continuing in the optional extension phase of the protocol due to continued good clinical response.